Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zai Lab Forms $165 Million Cancer Drug Partnership with MacroGenics

publication date: Nov 29, 2018

Zai Lab of Shanghai in-licensed greater China rights to three MacroGenics immunoncology candidates in an agreement worth up to $165 million. Zai will make an upfront payment of $25 million and be responsible for up to $140 million in milestone payments, plus royalties. MacroGenics, a Maryland company, is a clinical-stage biopharma that discovers innovative monoclonal antibodies for cancer. In addition to developing its own novel products, Zai in-licenses innovative medicines for cancer, autoimmune and infectious diseases for China use. More details....

Stock Symbols: (NSDQ: ZLAB) (NSDQ: MGNX)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.